Starpharma Holdings Limited (ASX:SPL)
Australia · Delayed Price · Currency is AUD 0.6800
-0.0150 (-2.16%)
Apr 20, 2026, 3:59 PM AEST
Starpharma Holdings Employees
Starpharma Holdings had 40 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
40
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
364.45K AUD
Profits / Employee
-80.78K AUD
Market Cap
292.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 40 | 0 | - |
| Jun 30, 2024 | 40 | -5 | -11.11% |
| Jun 30, 2023 | 45 | -5 | -10.00% |
| Jun 30, 2022 | 50 | 0 | - |
| Jun 30, 2021 | 50 | 5 | 11.11% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Starpharma Holdings News
- 3 years ago - Starpharma presents compelling data in Prostate Cancer at ESMO - PRNewsWire
- 4 years ago - Starpharma signs new DEP® agreement with MSD - PRNewsWire
- 4 years ago - Starpharma releases positive DEP® phase 2 interim results in prostate cancer - PRNewsWire
- 4 years ago - US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewsWire
- 5 years ago - Starpharma signs DEP® ADC Research Agreement with MSD - PRNewsWire
- 6 years ago - Starpharma to Webcast Live at Life Sciences Investor Forum September 17th - GlobeNewsWire
- 6 years ago - Starpharma’s SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2 - Business Wire
- 6 years ago - Starpharma creates slow release soluble DEP remdesivir nanoparticle - Business Wire